282 results about "Glaucoma present" patented technology

According to the glaucoma multi-mode auxiliary diagnosis device and the electronic equipment, firstly, first feature extraction and second feature extraction are carried out on an eye fundus image and an OCT image respectively, then semantic spaces of an eye fundus image mode and an OCT image mode are aligned by utilizing comparison loss, and the first feature and the second feature are fused by utilizing a cross attention mechanism, so that an eye fundus image is obtained. According to the method, the two modal data are subjected to fusion to obtain fusion features, then the fusion features are subjected to feature extraction to obtain third features, and glaucoma classification judgment is performed based on the third features, so that global modeling of the two modal data can be realized, effective features are extracted to perform glaucoma classification judgment, and the accuracy and timeliness of diagnosis are ensured.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device, tool, or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Some systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal. Other tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.

The invention relates to the technical field of glaucoma grading, and discloses a glaucoma grading system based on multi-modal conditional state space fusion, which comprises the following steps: acquiring a CFP image and an OCT image, and constructing a glaucoma grading network model which comprises a circular structure perception attention module, a layer prior enhancement axial attention module and a conditional state space fusion module; the circular structure perception attention module enhances the characterization capability of a circular key pathological change area in the CFP image, and the layer prior enhancement axial attention module enhances the utilization of key pathological change information in the OCT image; and the conditional state space fusion module dynamically modulates CFP spatial features through OCT global information, realizes cross-modal feature interaction, and performs glaucoma grading by using a trained network model. According to the method, multi-modal information can be effectively fused, the feature extraction capability of glaucoma related pathological features is enhanced, and the glaucoma grading performance is improved.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The invention belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof.The Ber-ApoEVs comprise ApoEVs and Ber supported by the ApoEVs, the ApoEVs are bone marrow mesenchymal stem cell-derived apoptosis vesicles, and the Ber is berberine and a derivative thereof. Researches show that brand new Ber-ApoEVs play a synergistic neuroprotective role in the aspects of regulating and controlling polarization of microglial cells, release of inflammatory factors, p38 / MAPK signals and the like, neuroinflammation caused by retinal ischemia reperfusion (IR) can be relieved, retinal neuron apoptosis can be inhibited, and the Ber-ApoEVs can be used for treating glaucoma.

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.

An adjustable flow glaucoma diverter is disclosed herein. For example, in one embodiment, an adjustable flow diverter may include an outflow drainage tube having a proximal inflow region and a distal outflow region. The proximal inflow region may include an aperture defining a fluid inlet range disposed at a location allowing fluid to flow therethrough. The diverter also includes an inflow control assembly located at the proximal inflow region. The inflow control assembly may include a control element configured to slidably mate with the proximal inflow region and a spring element. The spring element is configured to be activated by non-invasive energy and, upon activation, slidably move the control element along the proximal inflow region such that (a) the one or more apertures are accessible and have a first fluid flow cross-section, or (b) the one or more apertures are at least partially covered by the control element and have a second, different fluid flow cross-section.

The present disclosure describes an optical probe for applying a laser light to at least the flat portion of the ciliary body and optionally other areas, such as the trabecular mesh, the ciliary crown and / or the ciliary sulcus of the eye, the present invention relates to methods, such as for treating glaucoma, reducing intraocular pressure (IOP), improving the outflow of aqueous humor from the eye, and / or reducing the accumulation of aqueous humor within the eye. The optical probe may be adapted for simultaneous treatment of a plurality of different regions, tissues, or eye bodies of the eye, or for sequential treatment of a plurality of different regions, tissues, or eye bodies of the eye.

The present invention discloses the use of a BCL3 inhibitor in the preparation of a drug for treating glaucoma. The present invention discovers the role of the BCL3 / NF-κB / NLRP3 signaling pathway in glaucoma and demonstrates that BCL3 inhibitors (such as JS-6) have never been reported to reduce retinal ganglion cell apoptosis and pyroptosis, and are therefore useful in treating glaucoma-related diseases.

The invention provides an ophthalmology minimally invasive drainage device, and relates to the technical field of medical instruments. The device comprises a drainage tube, a dispersion tube and a release tube which are fixed into a whole, the longitudinal sections of the drainage tube, the dispersion tube and the release tube are flat, and a liquid inlet assembly used for liquid inlet is arranged at the left end of the drainage tube; the upper part of the drainage tube is provided with a fixing assembly for limiting an operation line; the dispersing pipe is fixedly connected with a fixing lug; the releasing pipe is in a circular arc shape, a pressure stabilizing film is arranged at the right end of the releasing pipe, and a pressure stabilizing opening is formed between the pressure stabilizing film and the releasing pipe. Through the arranged fixing assembly, the operation line can be limited, the stability of the drainage tube is guaranteed, the operation quality is improved, and operation complications are reduced; through the arrangement of the pressure stabilizing film and the pressure stabilizing opening, the size of the pressure stabilizing opening can be changed by utilizing the characteristic that the pressure stabilizing film deforms under pressure, the stable pressure of aqueous humor in the anterior chamber is ensured, and treatment of glaucoma is facilitated.

In specific embodiments, provided is a material for preventing adhesion of membranes in an ophthalmic surgery for treatment of glaucoma or the like without using mitomycin-C or the like. Particularly provided is such material, which is easy to handle and has no risk of histolysis or infections. In a production method of a preferred embodiment, prepared are: aldehyde-modified dextran (first reactant) having weight-average molecular weight of 10,000-5,000,000 and introduced aldehyde group-per-anhydrous glucose unit (mol / AGU) of 0.4-0.7; and succinic anhydride-added poly-L-lysine (second reactant) having weight-average molecular weight of 1000-100,000 and having residual amino group ratio of 80-99%; then, they are mixed together so that aldehyde group-to-amino group molar ratio becomes 0.9-1.1 and are reacted in presence of water so that polymer concentration becomes 8-20%; and a hydrogel produced by the reaction, or a suspension before gelation, is freeze-dried to produce a porous sheet having a thickness of 0.1-0.8 mm.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The present technology provides systems, devices, and methods for forming blebs to treat ocular hypertension or glaucoma. In some embodiments, a minimally invasive bleb formation device comprises an introducer sheath having a lumen extending longitudinally therethrough. The lumen has a distal end aperture insertable adjacent to a target tissue. The device further includes a wire positionable within the lumen of the introducer sheath. The wire has a first end portion, a second end portion, and an intermediate region between the first end portion and the second end portion. At least a segment of the intermediate portion is configured to extend through the distal end aperture to form a wire loop. The wire loop is moveable between a plurality of positions and is configured to disrupt and cauterize the target tissue.

The invention provides a gRNA, an AAV expression vector and a CRISPR-CasRx system for treating glaucoma, and particularly provides (a) a gene editing protein or an expression vector thereof, the gene editing protein comprises a VI type Cas protein; and (b) gRNA or an expression vector thereof, the gRNA is RNA for guiding the gene editing protein to be specifically combined with an aqueous humor outflow related gene and / or an aqueous humor generation related gene in an eye tissue, the aqueous humor outflow related gene comprises Rock1 and Rock2, and the aqueous humor generation related gene comprises Aqp1 and Adrb2. The gRNA designed aiming at exon regions of aqueous fluid outflow related genes (such as Rock1 and Rock2) and aqueous fluid generation related genes (such as Aqp1 and Adrb2) has the characteristics of relatively high editing efficiency and relatively low off-target rate, and the combination of the VI type Cas protein and the gRNA designed by the invention can effectively prevent and / or treat glaucoma or ocular hypertension.

Provided herein are solid forms, e.g., polymorphs, of 2-(3-((7R,8aS)-7-fluorohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-1-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azetidin-3-yl)acetonitrile, which are useful for treating kinase-related diseases or disorders. The solid forms, and compositions thereof, are useful for treating diseases in a subject, including, but not limited to, ocular diseases such as glaucoma, ocular hypertension, ocular wound repair, neurodegenerative ocular diseases, retinal detachment, and non-ocular diseases such as nerve injury, or skin wound repair, or inflammatory diseases, among others. (Compound 1) TIFF2026501674000028.tif4839

The present invention provides boron-containing isoquinoline compounds as protein kinase-modulating compounds. These compounds are useful as neuroprotective and neuro-regenerative agents for the amelioration of glaucoma and other ocular neuropathies.

Aqueous topical ophthalmic pharmaceutical formulations are provided that deliver an effective amount of (lev)cromakalim or a pharmaceutically acceptable salt thereof to treat anterior or posterior ocular disorders that respond to (lev)cromakalim, including glaucoma.

The present disclosure provides compositions comprising at least one compound of Formula (I), suitable for application to the ocular surface. The present disclosure also provides methods of making compositions comprising at least one compound of Formula (I). The present disclosure further provides methods of using compositions comprising at least one compound of Formula (I) to reduce intraocular pressure, provide neuroprotection, and / or treat ocular conditions such as glaucoma.

The utility model relates to a glaucoma drainage tube with double drainage discs, which belongs to the technical field of medical artificial implants and comprises a drainage tube body, a drainage mechanism is arranged on the right side of the drainage tube body and comprises a fixing structure fixedly mounted on the outer side of the drainage tube, and the double-layer drainage discs are fixedly mounted on the right side of the fixing structure. The glaucoma drainage tube with the double drainage discs can be easily implanted into an anterior chamber corner during an operation, can be accurately butted with an aqueous fluid generation source, ensures that aqueous fluid flows in without hindrance, lays a solid foundation for subsequent drainage, can be tightly attached to a sclera by virtue of the characteristics of the fixing structure, greatly reduces the displacement risk of an implant, ensures stable operation of a whole drainage system, and has a good application prospect. The upper drainage disc and the lower drainage disc cooperatively operate, the conjunctival sac is accurately opened, a stable filtering bubble is formed, the drainage groove matched with the drainage tube body in the drainage tube forms a smooth aqueous humor channel, aqueous humor drainage is accelerated, the supporting structure efficiently promotes aqueous humor diffusion between the two layers of drainage discs, and the drainage efficiency is comprehensively optimized.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

Provided is a method for treating a condition selected from the group consisting of pain, sleep disorder, cancer, Alzheimer's disease, neurodegenerative diseases, ulcer, hypertension, opioid- related adverse effects, inflammation, asthma, glaucoma, neurodevelopment diseases and combinations thereof in a subject in need thereof, the method comprising administering to the subject: a) a first active pharmaceutical ingredient (API) comprising at least one cannabinoid other than CBD and THC; and b) a second API, which is different from the first API.

Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.

This invention relates to the field of traditional Chinese medicine (TCM) technology. The invention provides a TCM composition for treating glaucoma and its preparation method, comprising the following components in parts by weight: 18-28 parts of Cassia seed, 12-18 parts of Lycium fruit, 12-18 parts of Eriocaulon buergerianum, 10-15 parts of vinegar-processed Cyperus rotundus, 10-15 parts of mulberry leaf, 10-15 parts of Ligusticum chuanxiong, 8-12 parts of Polyporus umbellatus, 5-8 parts of Pueraria lobata, 5-8 parts of Akebia quinata, 3-5 parts of Curcuma longa, 3-5 parts of Indigo naturalis, and 2-4 parts of prepared licorice root. The TCM composition of this invention has a strong effect in lowering intraocular pressure, improving retinal blood supply, and preventing optic nerve atrophy caused by glaucoma; simultaneously, the processing method maximizes the retention of the active pharmaceutical ingredients. Furthermore, the technical solution of this invention achieves a dual improvement in efficacy and safety, and also reduces the recurrence rate and side effects.